Cannabis and ALS (Amyotrophic Lateral Sclerosis)

Not Medical Advice

This article is not medical advice. It is an evidence summary for educational use. ALS is a serious, progressive, terminal disease. Do not start, stop, or change any treatment — including cannabis — without talking to a neurologist familiar with motor neuron disease. Cannabis can interact with medications, sedatives, and respiratory function, all of which matter enormously in ALS.

Plain-Language Summary

Amyotrophic lateral sclerosis (ALS) is a progressive disease that kills motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and eventually respiratory failure. Median survival is roughly 3–5 years from symptom onset ^[1]. There is no cure. Approved disease-modifying drugs (riluzole, edaravone, and in the US, tofersen for SOD1-mutation ALS) extend survival modestly ^[2][3].

Cannabis has been proposed for ALS for two reasons: (1) anecdotal reports that it helps with symptoms like cramps, spasticity, and sleep, and (2) preclinical (animal and cell) studies suggesting cannabinoids might be neuroprotective ^[4]. The symptomatic claims are plausible and partially supported. The neuroprotection claims have not translated to humans.

What Probably Works (Symptomatic)

Spasticity. The strongest cannabis-and-neurology evidence comes from multiple sclerosis, where nabiximols (Sativex, a 1:1 THC:CBD oromucosal spray) is approved in many countries for spasticity ^[5]. A randomized controlled trial in ALS patients (CANALS, Riva et al. 2019) tested nabiximols specifically for spasticity in motor neuron disease and found a statistically significant improvement on the Numerical Rating Scale for spasticity vs placebo, with acceptable tolerability ^[6]. [evidence:moderate] This is the single best ALS-specific cannabis trial to date.

Cramps and muscle stiffness. Often grouped with spasticity in clinical reports; the CANALS trial captured improvements here as well ^[6]. Weak / limited

Sleep. THC-dominant cannabis is sedating and shortens sleep onset in the short term in general populations [evidence:moderate], though tolerance develops and REM is suppressed ^[7]. No ALS-specific RCT, but sleep is frequently disrupted in ALS by cramps, anxiety, and respiratory issues, and patients commonly report subjective benefit. Anecdote

What Might Work (Weak Evidence)

Sialorrhea (excess saliva / drooling). THC has anticholinergic-like drying effects and some clinicians use it adjunctively. Evidence is largely anecdotal and case-report level. Weak / limited

Appetite and weight loss. Cachexia is a poor prognostic sign in ALS ^[1]. THC and dronabinol increase appetite in HIV wasting and cancer contexts [evidence:moderate], and extrapolation to ALS is reasonable but not directly tested in adequately powered trials. Weak / limited

Pain. Musculoskeletal and neuropathic pain are common in ALS. Cannabis has moderate evidence for chronic pain generally ^[8], but no ALS-specific pain trials. Weak / limited

Pseudobulbar affect and anxiety. Anecdotal patient reports. No controlled data in ALS. Anecdote

What Doesn't Work or Has Weak/No Evidence

Disease modification / neuroprotection / survival. This is the big one. SOD1 transgenic mouse studies showed that cannabinoids (Δ9-THC, cannabinol, WIN 55,212-2) modestly delayed disease onset or progression in animals ^[4][9]. This has never been replicated in a human trial. The SOD1 mouse is also a notoriously poor predictor of clinical success — dozens of drugs have worked in the mouse and failed in patients ^[10]. Claims that cannabis 'slows ALS' or 'stops ALS progression' in humans are not supported by evidence. No data

CBD as monotherapy for ALS. No human RCT supports this. No data

'Rick Simpson Oil' or high-dose THC oil protocols as a cure. No clinical evidence. These claims rely on testimonials, not trials. No data

What We Don't Know

• Whether cannabinoids meaningfully affect ALS progression in humans (likely not, but never adequately tested).
• Optimal THC:CBD ratio, dose, or route of administration for ALS symptoms.
• Long-term safety in patients with declining respiratory function — a critical gap, because smoking anything is a bad idea in ALS and even vaporized THC has cardiopulmonary effects Weak / limited.
• Interactions with riluzole, edaravone, and tofersen. CBD inhibits several CYP450 enzymes (notably CYP3A4 and CYP2C19) and could plausibly alter levels of co-administered drugs ^[11]. [evidence:moderate for the interaction mechanism; evidence:none for clinical outcomes in ALS specifically]
• Whether bulbar-onset patients (who have swallowing difficulty) can safely use oromucosal sprays.

Comparison With Standard ALS Treatments

Disease-modifying drugs. Riluzole extends median survival by roughly 2–3 months ^[2]. Edaravone may slow functional decline in a subset of patients ^[3]. Tofersen targets SOD1-mutation ALS specifically ^[12]. Cannabis does not belong in this category — it has no demonstrated effect on survival or ALSFRS-R progression.

Symptom management standard of care. Baclofen, tizanidine, and benzodiazepines for spasticity; quinine sulfate or levetiracetam for cramps; glycopyrrolate, atropine drops, or botulinum toxin for sialorrhea; non-invasive ventilation for respiratory support; multidisciplinary clinic care, which itself extends survival ^[13]. Cannabis is best understood as a possible add-on for refractory symptoms, not a replacement for any of these.

The CANALS trial positioned nabiximols as adjunctive — added on top of existing antispastic medication — which is the realistic clinical framing ^[6].

Risks and Practical Considerations

• Respiratory function. ALS commonly causes diaphragmatic and intercostal weakness. Smoking cannabis is a particularly bad idea. Vaporization, tinctures, oromucosal sprays, and edibles are safer routes [evidence:moderate].
• Sedation and falls. THC impairs balance and coordination. ALS patients are already fall-prone. Start very low.
• Cognitive effects. Up to half of ALS patients have some cognitive change, and a smaller subset develop frontotemporal dementia ^[14]. THC can worsen cognitive symptoms.
• Drug interactions. CBD inhibits CYP450 enzymes; ask a pharmacist to review your full medication list ^[11].
• Cost and access. Pharmaceutical-grade nabiximols is expensive and not available everywhere. Dispensary products vary wildly in cannabinoid content and consistency.
• Hypotension, tachycardia, and dry mouth are common acute side effects.

If you and your neurologist decide to try cannabis for symptoms, the conservative approach is: a balanced or CBD-dominant product, oromucosal or oral route, very low starting dose, slow titration, and clear target symptoms so you can tell whether it's actually helping.

Sources

How this page was made

Related

• Cannabis and Chronic Pain — What the evidence actually says about cannabis for long-term pain, separated from the mark...